Proteolysis targeting chimeras (PROTACs) have surged in popularity as a drug modality owing to their ability to degrade pathogenic proteins. Despite their advantages over conventional inhibitors, PROTAC discovery still requires high-affinity warheads, but ligands for undruggable proteins are difficu...
ORGANISM(S): Homo sapiens (Human)
